Lymphoma Therapeutics
1. Beleodaq patent expiration
Treatment: Treatment of patients with relapsed or refractory peripheral t-cell lymphoma (ptcl).
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6888027 | ACROTECH BIOPHARMA | Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors |
Aug, 2026
(6 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8835501 | ACROTECH BIOPHARMA | Pharmaceutical formulations of HDAC inhibitors |
Oct, 2027
(1 year, 9 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 03, 2019 |
| Orphan Drug Exclusivity(ODE) | Jul 03, 2021 |
| Orphan Drug Exclusivity(ODE-68) | Jul 03, 2021 |
Drugs and Companies using BELINOSTAT ingredient
NCE-1 date: 03 July, 2018
Market Authorisation Date: 03 July, 2014
Dosage: POWDER
How can I launch a generic of BELEODAQ before it's drug patent expiration?
More Information on Dosage
BELEODAQ family patents
2. Brukinsa patent expiration
Treatment: Treatment of adult patients with relapsed or refractory follicular lymphoma (fl), in combination with obinutuzumab, after two or more lines ...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9447106 | BEONE MEDICINES USA | Substituted pyrazolo[1,5-a]pyrimidines as bruton's tyrosine kinase modulators |
Apr, 2034
(8 years from now) | |
| US11851437 | BEONE MEDICINES USA | Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof |
Aug, 2037
(11 years from now) | |
| US10927117 | BEONE MEDICINES USA | Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof |
Aug, 2037
(11 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11701357 | BEONE MEDICINES USA | Treatment of B cell cancers using a combination comprising Btk inhibitors |
Jun, 2039
(13 years from now) | |
| US11884674 | BEONE MEDICINES USA | Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra- hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof |
Aug, 2037
(11 years from now) | |
| US11911386 | BEONE MEDICINES USA | Methods of treating B-cell proliferative disorder |
Jan, 2043
(17 years from now) | |
| US11591340 | BEONE MEDICINES USA | Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra- hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof |
Aug, 2037
(11 years from now) | |
| US10570139 | BEONE MEDICINES USA | Substituted pyrazolo[1,5-a]pyrimidines as Bruton's tyrosine kinase modulators |
Apr, 2034
(8 years from now) | |
| US11896596 | BEONE MEDICINES USA | Methods of treating B-cell proliferative disorder |
Jan, 2043
(17 years from now) | |
| US11786531 | BEONE MEDICINES USA | Methods of treating B-cell proliferative disorder |
Jan, 2043
(17 years from now) | |
| US11970500 | BEONE MEDICINES USA | Crystalline form of (s)-7-(1-acryloylpiperidin-4-yl)- 2-(4-phenoxyphenyl)-4,5,6,7-tetra- hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof |
Aug, 2037
(11 years from now) | |
| US11142528 | BEONE MEDICINES USA | Substituted pyrazolo[1,5-a]pyrimidines as Bruton's tyrosine kinase modulators |
Apr, 2034
(8 years from now) | |
| US12233069 | BEONE MEDICINES USA | Oral solid tablet comprising Bruton's Tyrosine Kinase inhibitor and preparation method therefor |
Jun, 2040
(14 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-871) | Aug 31, 2024 |
| New Indication(I-874) | Sep 14, 2024 |
| New Chemical Entity Exclusivity(NCE) | Nov 14, 2024 |
| New Indication(I-817) | Jan 19, 2026 |
| Orphan Drug Exclusivity(ODE-276) | Nov 14, 2026 |
| New Indication(I-936) | Mar 07, 2027 |
| Orphan Drug Exclusivity(ODE-371) | Aug 31, 2028 |
| Orphan Drug Exclusivity(ODE-370) | Sep 14, 2028 |
| Orphan Drug Exclusivity(ODE-274) | Jan 19, 2030 |
| ODE*(ODE*) | Mar 07, 2031 |
| Orphan Drug Exclusivity(ODE-467) | Mar 07, 2031 |
Drugs and Companies using ZANUBRUTINIB ingredient
NCE-1 date: 15 November, 2023
Market Authorisation Date: 14 November, 2019
Dosage: CAPSULE; TABLET
More Information on Dosage
BRUKINSA family patents
3. Calquence patent
expiration
Treatment: Treatment of adult patients with chronic lymphocytic leukemia; Treatment of adult patients with previously untreated mantle cell lymphoma wh...
CALQUENCE's oppositions filed in EPO
CALQUENCE IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7459554 | ASTRAZENECA | Imidazopyrazine tyrosine kinase inhibitors |
Nov, 2026
(10 months from now) | |
| US9796721 | ASTRAZENECA | Crystal forms of (S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide |
Jul, 2036
(10 years from now) | |
| US9290504 | ASTRAZENECA | 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as Btk inhibitors |
Jul, 2032
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10239883 | ASTRAZENECA | 4-imidazopyridazin-1-yl-benzamides as BTK inhibitors |
Jul, 2032
(6 years from now) | |
| US10272083 | ASTRAZENECA | Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor |
Jan, 2035
(9 years from now) | |
| US11771696 | ASTRAZENECA | Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor |
Jan, 2035
(9 years from now) | |
| US10167291 | ASTRAZENECA | Pharmaceutical composition comprising a crystal form of (S)-4-(8-amino-3-(1-(but-2-ynoyl) pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide |
Jul, 2036
(10 years from now) | |
| US9758524 | ASTRAZENECA | 4-imidazopyridazin-1-yl-benzamides as Btk inhibitors |
Jul, 2032
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 31, 2022 |
| New Indication(I-817) | Nov 21, 2022 |
| Orphan Drug Exclusivity(ODE-175) | Oct 31, 2024 |
| Orphan Drug Exclusivity(ODE-274) | Nov 21, 2026 |
| New Indication(I-960) | Jan 16, 2028 |
Drugs and Companies using ACALABRUTINIB ingredient
NCE-1 date: 31 October, 2021
Market Authorisation Date: 31 October, 2017
Dosage: CAPSULE
How can I launch a generic of CALQUENCE before it's drug patent expiration?
More Information on Dosage
CALQUENCE family patents
4. Calquence patent expiration
Treatment: Treatment of adult patients with previously untreated chronic lymphocytic leukemia or small lymphocytic leukemia in combination with obinutuzumab by administering 100 mg of acalabrutinib twice daily; ...
CALQUENCE's oppositions filed in EPO
CALQUENCE IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11059829 | ASTRAZENECA | Crystal forms of (S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide maleate |
Jul, 2036
(10 years from now) | |
| US7459554 | ASTRAZENECA | Imidazopyrazine tyrosine kinase inhibitors |
Nov, 2026
(10 months from now) | |
| US9290504 | ASTRAZENECA | 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as Btk inhibitors |
Jul, 2032
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10272083 | ASTRAZENECA | Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor |
Jan, 2035
(9 years from now) | |
| US11771696 | ASTRAZENECA | Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor |
Jan, 2035
(9 years from now) | |
| US10239883 | ASTRAZENECA | 4-imidazopyridazin-1-yl-benzamides as BTK inhibitors |
Jul, 2032
(6 years from now) | |
| US9758524 | ASTRAZENECA | 4-imidazopyridazin-1-yl-benzamides as Btk inhibitors |
Jul, 2032
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 31, 2022 |
| New Indication(I-817) | Nov 21, 2022 |
| Orphan Drug Exclusivity(ODE-175) | Oct 31, 2024 |
| Orphan Drug Exclusivity(ODE-274) | Nov 21, 2026 |
| New Indication(I-960) | Jan 16, 2028 |
Drugs and Companies using ACALABRUTINIB MALEATE ingredient
NCE-1 date: 31 October, 2021
Market Authorisation Date: 03 August, 2022
Dosage: TABLET
More Information on Dosage
CALQUENCE family patents
5. Folotyn patent expiration
Treatment: Treatment of patients with relapsed or refractory peripheral t-cell lymphoma
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6028071 | ACROTECH BIOPHARMA | Purified compositions of 10-propargyl-10-deazaaminopterin and methods of using same in the treatment of tumors |
Jul, 2022
(3 years ago) | |
| US8299078 | ACROTECH BIOPHARMA | Treatment of T-cell lymphoma using 10-propargyl-10-deazaaminopterin |
May, 2025
(7 months ago) | |
| US7622470 | ACROTECH BIOPHARMA | Treatment of T-cell lymphoma using 10-propargyl-10-deazaaminopterin |
May, 2025
(7 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 24, 2014 |
| Orphan Drug Exclusivity(ODE) | Sep 24, 2016 |
Drugs and Companies using PRALATREXATE ingredient
NCE-1 date: 24 September, 2013
Market Authorisation Date: 24 September, 2009
Dosage: SOLUTION
How can I launch a generic of FOLOTYN before it's drug patent expiration?
More Information on Dosage
FOLOTYN family patents
6. Imbruvica patent expiration
Treatment: Treatment of marginal zone lymphoma; Treatment of mantle cell lymphoma; Treatmen...
IMBRUVICA's oppositions filed in EPO
IMBRUVICA IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9296753 | PHARMACYCLICS LLC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Oct, 2033
(7 years from now) | |
| US9181257 | PHARMACYCLICS LLC | Inhibitors of Bruton's tyrosine kinase |
Dec, 2026
(11 months from now) | |
| US8957079 | PHARMACYCLICS LLC | Inhibitors of Bruton's tyrosine kinase |
Dec, 2026
(11 months from now) | |
| US8735403 | PHARMACYCLICS LLC | Inhibitors of Bruton's tyrosine kinase |
Dec, 2026
(11 months from now) | |
| US7514444 | PHARMACYCLICS LLC | Inhibitors of bruton's tyrosine kinase |
Dec, 2026
(11 months from now) | |
| US10125140 | PHARMACYCLICS LLC | Crystalline forms of a bruton's tyrosine kinase inhibitor |
Jun, 2033
(7 years from now) | |
| US10106548 | PHARMACYCLICS LLC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Jun, 2033
(7 years from now) | |
| US9725455 | PHARMACYCLICS LLC | Crystalline forms of a bruton's tyrosine kinase inhibitor |
Jun, 2033
(7 years from now) | |
| US8008309 | PHARMACYCLICS LLC | Inhibitors of bruton's tyrosine kinase |
Nov, 2027
(1 year, 10 months from now) | |
| US8697711 | PHARMACYCLICS LLC | Inhibitors of bruton'S tyrosine kinase |
Dec, 2026
(11 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US8563563 (Pediatric) | PHARMACYCLICS LLC | Inhibitors of bruton's tyrosine kinase |
Oct, 2027
(1 year, 9 months from now) | |
| US9814721 | PHARMACYCLICS LLC | Use of inhibitors of bruton'S tyrosine kinase (BTK) |
Jun, 2031
(5 years from now) | |
| US10653696 | PHARMACYCLICS LLC | Use of inhibitors of bruton's tyrosine kinase (BTK) |
Jun, 2031
(5 years from now) | |
| US8999999 | PHARMACYCLICS LLC | Use of inhibitors of Bruton's tyrosine kinase (Btk) |
Jun, 2031
(5 years from now) | |
|
US9814721 (Pediatric) | PHARMACYCLICS LLC | Use of inhibitors of bruton'S tyrosine kinase (BTK) |
Dec, 2031
(5 years from now) | |
|
US10653696 (Pediatric) | PHARMACYCLICS LLC | Use of inhibitors of bruton's tyrosine kinase (BTK) |
Dec, 2031
(5 years from now) | |
| US10004746 | PHARMACYCLICS LLC | Use of inhibitors of Bruton's tyrosine kinase (Btk) |
Jun, 2031
(5 years from now) | |
| US10016435 | PHARMACYCLICS LLC | Use of inhibitors of Bruton's tyrosine kinase (Btk) |
Jun, 2031
(5 years from now) | |
| US9801881 | PHARMACYCLICS LLC | Use of inhibitors of bruton's tyrosine kinase (BTK) |
Jun, 2031
(5 years from now) | |
| US9801883 | PHARMACYCLICS LLC | Use of inhibitors of bruton's tyrosine kinase (Btk) |
Jun, 2031
(5 years from now) | |
| US9125889 | PHARMACYCLICS LLC | Use of inhibitors of Bruton's tyrosine kinase (Btk) |
Jun, 2031
(5 years from now) | |
| US8476284 | PHARMACYCLICS LLC | Inhibitors of Bruton's tyrosine kinase |
Dec, 2026
(11 months from now) | |
| US8754090 | PHARMACYCLICS LLC | Use of inhibitors of bruton's tyrosine kinase (Btk) |
Jun, 2031
(5 years from now) | |
| US10463668 | PHARMACYCLICS LLC | Methods of treating and preventing graft versus host disease |
Oct, 2034
(8 years from now) | |
| US10695350 | PHARMACYCLICS LLC | Methods of treating and preventing graft versus host disease |
Oct, 2034
(8 years from now) | |
| US8563563 | PHARMACYCLICS LLC | Inhibitors of bruton's tyrosine kinase |
Apr, 2027
(1 year, 3 months from now) | |
| US8703780 | PHARMACYCLICS LLC | Inhibitors of Bruton's tyrosine kinase |
Dec, 2026
(11 months from now) | |
| US8952015 | PHARMACYCLICS LLC | Inhibitors of Bruton's tyrosine kinase |
Dec, 2026
(11 months from now) | |
| US11672803 | PHARMACYCLICS LLC | Use of inhibitors of Brutons tyrosine kinase (Btk) |
Jun, 2031
(5 years from now) | |
| US8497277 | PHARMACYCLICS LLC | Inhibitors of Bruton's tyrosine kinase |
Dec, 2026
(11 months from now) | |
| US10478439 | PHARMACYCLICS LLC | Use of inhibitors of bruton's tyrosine kinase (Btk) |
Jun, 2031
(5 years from now) | |
| US10751342 | PHARMACYCLICS LLC | Use of inhibitors of Bruton's tyrosine kinase (Btk) |
Jun, 2031
(5 years from now) | |
| US10961251 | PHARMACYCLICS LLC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Jun, 2033
(7 years from now) | |
|
US8754090 (Pediatric) | PHARMACYCLICS LLC | Use of inhibitors of bruton's tyrosine kinase (Btk) |
Dec, 2031
(5 years from now) | |
| US9795604 | PHARMACYCLICS LLC | Methods of treating and preventing graft versus host disease |
Oct, 2034
(8 years from now) | |
| US9540382 | PHARMACYCLICS LLC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Aug, 2033
(7 years from now) | |
| US8754091 | PHARMACYCLICS LLC | Inhibitors of bruton's tyrosine kinase |
Dec, 2026
(11 months from now) | |
| US10010507 | PHARMACYCLICS LLC | Pharmaceutical formulations of a bruton's tyrosine kinase inhibitor |
Mar, 2036
(10 years from now) | |
| US10213386 | PHARMACYCLICS LLC | Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor |
Mar, 2036
(10 years from now) | |
| US10752634 | PHARMACYCLICS LLC | Crystalline forms of a brutons tyrosine kinase inhibitor |
Jun, 2033
(7 years from now) | |
| US9713617 | PHARMACYCLICS LLC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Jun, 2033
(7 years from now) | |
| US10294231 | PHARMACYCLICS LLC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Jun, 2033
(7 years from now) | |
| US10294232 | PHARMACYCLICS LLC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Jun, 2033
(7 years from now) | |
| US9655857 | PHARMACYCLICS LLC | Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor |
Mar, 2036
(10 years from now) | |
| US10828259 | PHARMACYCLICS LLC | Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor |
Mar, 2036
(10 years from now) | |
| US12364698 | PHARMACYCLICS LLC | NA |
Apr, 2036
(10 years from now) | |
| US12201690 | PHARMACYCLICS LLC | Formulations/compositions comprising ibrutinib |
Jun, 2039
(13 years from now) | |
|
US8008309 (Pediatric) | PHARMACYCLICS LLC | Inhibitors of bruton's tyrosine kinase |
May, 2028
(2 years from now) | |
|
US7514444 (Pediatric) | PHARMACYCLICS LLC | Inhibitors of bruton's tyrosine kinase |
Jun, 2027
(1 year, 5 months from now) | |
|
US8476284 (Pediatric) | PHARMACYCLICS LLC | Inhibitors of Bruton's tyrosine kinase |
Jun, 2027
(1 year, 5 months from now) | |
|
US8497277 (Pediatric) | PHARMACYCLICS LLC | Inhibitors of Bruton's tyrosine kinase |
Jun, 2027
(1 year, 5 months from now) | |
|
US8754091 (Pediatric) | PHARMACYCLICS LLC | Inhibitors of bruton's tyrosine kinase |
Jun, 2027
(1 year, 5 months from now) | |
|
US8697711 (Pediatric) | PHARMACYCLICS LLC | Inhibitors of bruton'S tyrosine kinase |
Jun, 2027
(1 year, 5 months from now) | |
|
US8703780 (Pediatric) | PHARMACYCLICS LLC | Inhibitors of Bruton's tyrosine kinase |
Jun, 2027
(1 year, 5 months from now) | |
|
US8735403 (Pediatric) | PHARMACYCLICS LLC | Inhibitors of Bruton's tyrosine kinase |
Jun, 2027
(1 year, 5 months from now) | |
|
US9125889 (Pediatric) | PHARMACYCLICS LLC | Use of inhibitors of Bruton's tyrosine kinase (Btk) |
Dec, 2031
(5 years from now) | |
|
US8957079 (Pediatric) | PHARMACYCLICS LLC | Inhibitors of Bruton's tyrosine kinase |
Jun, 2027
(1 year, 5 months from now) | |
|
US9181257 (Pediatric) | PHARMACYCLICS LLC | Inhibitors of Bruton's tyrosine kinase |
Jun, 2027
(1 year, 5 months from now) | |
|
US9296753 (Pediatric) | PHARMACYCLICS LLC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Apr, 2034
(8 years from now) | |
|
US9795604 (Pediatric) | PHARMACYCLICS LLC | Methods of treating and preventing graft versus host disease |
Apr, 2035
(9 years from now) | |
|
US10004746 (Pediatric) | PHARMACYCLICS LLC | Use of inhibitors of Bruton's tyrosine kinase (Btk) |
Dec, 2031
(5 years from now) | |
|
US9801883 (Pediatric) | PHARMACYCLICS LLC | Use of inhibitors of bruton's tyrosine kinase (Btk) |
Dec, 2031
(5 years from now) | |
|
US9801881 (Pediatric) | PHARMACYCLICS LLC | Use of inhibitors of bruton's tyrosine kinase (BTK) |
Dec, 2031
(5 years from now) | |
|
US8952015 (Pediatric) | PHARMACYCLICS LLC | Inhibitors of Bruton's tyrosine kinase |
Jun, 2027
(1 year, 5 months from now) | |
|
US8999999 (Pediatric) | PHARMACYCLICS LLC | Use of inhibitors of Bruton's tyrosine kinase (Btk) |
Dec, 2031
(5 years from now) | |
|
US9540382 (Pediatric) | PHARMACYCLICS LLC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Feb, 2034
(8 years from now) | |
|
US9713617 (Pediatric) | PHARMACYCLICS LLC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Dec, 2033
(7 years from now) | |
|
US9725455 (Pediatric) | PHARMACYCLICS LLC | Crystalline forms of a bruton's tyrosine kinase inhibitor |
Dec, 2033
(7 years from now) | |
|
US10016435 (Pediatric) | PHARMACYCLICS LLC | Use of inhibitors of Bruton's tyrosine kinase (Btk) |
Dec, 2031
(5 years from now) | |
|
US10106548 (Pediatric) | PHARMACYCLICS LLC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Dec, 2033
(7 years from now) | |
|
US10125140 (Pediatric) | PHARMACYCLICS LLC | Crystalline forms of a bruton's tyrosine kinase inhibitor |
Dec, 2033
(7 years from now) | |
|
US10294232 (Pediatric) | PHARMACYCLICS LLC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Dec, 2033
(7 years from now) | |
|
US10294231 (Pediatric) | PHARMACYCLICS LLC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Dec, 2033
(7 years from now) | |
|
US10751342 (Pediatric) | PHARMACYCLICS LLC | Use of inhibitors of Bruton's tyrosine kinase (Btk) |
Dec, 2031
(5 years from now) | |
|
US10752634 (Pediatric) | PHARMACYCLICS LLC | Crystalline forms of a brutons tyrosine kinase inhibitor |
Dec, 2033
(7 years from now) | |
|
US10478439 (Pediatric) | PHARMACYCLICS LLC | Use of inhibitors of bruton's tyrosine kinase (Btk) |
Dec, 2031
(5 years from now) | |
|
US10961251 (Pediatric) | PHARMACYCLICS LLC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Dec, 2033
(7 years from now) | |
|
US10463668 (Pediatric) | PHARMACYCLICS LLC | Methods of treating and preventing graft versus host disease |
Apr, 2035
(9 years from now) | |
|
US10695350 (Pediatric) | PHARMACYCLICS LLC | Methods of treating and preventing graft versus host disease |
Apr, 2035
(9 years from now) | |
|
US9655857 (Pediatric) | PHARMACYCLICS LLC | Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor |
Sep, 2036
(10 years from now) | |
|
US10010507 (Pediatric) | PHARMACYCLICS LLC | Pharmaceutical formulations of a bruton's tyrosine kinase inhibitor |
Sep, 2036
(10 years from now) | |
|
US10213386 (Pediatric) | PHARMACYCLICS LLC | Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor |
Sep, 2036
(10 years from now) | |
|
US10828259 (Pediatric) | PHARMACYCLICS LLC | Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor |
Sep, 2036
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-680) | Feb 12, 2017 |
| New Indication(I-689) | Jul 28, 2017 |
| New Indication(I-702) | Jan 29, 2018 |
| New Chemical Entity Exclusivity(NCE) | Nov 13, 2018 |
| New Indication(I-729) | Mar 04, 2019 |
| New Dosing Schedule(D-165) | May 06, 2019 |
| New Indication(I-736) | May 06, 2019 |
| New Indication(I-737) | May 06, 2019 |
| New Indication(I-741) | Jan 18, 2020 |
| New Indication(I-753) | Aug 02, 2020 |
| Orphan Drug Exclusivity(ODE-55) | Nov 13, 2020 |
| Orphan Drug Exclusivity(ODE-60) | Feb 12, 2021 |
| Orphan Drug Exclusivity(ODE-72) | Jul 28, 2021 |
| New Dosing Schedule(D-176) | Aug 24, 2021 |
| M(M-236) | Jan 25, 2022 |
| Orphan Drug Exclusivity(ODE-86) | Jan 29, 2022 |
| Orphan Drug Exclusivity(ODE-109) | Mar 04, 2023 |
| Orphan Drug Exclusivity(ODE-117) | May 06, 2023 |
| Orphan Drug Exclusivity(ODE-128) | Jan 18, 2024 |
| Orphan Drug Exclusivity(ODE) | Aug 02, 2024 |
| ODE*(ODE*) | Aug 02, 2024 |
| Orphan Drug Exclusivity(ODE-152) | Aug 02, 2024 |
| M(M-14) | Aug 24, 2025 |
| New Product(NP) | Aug 24, 2025 |
| New Patient Population(NPP) | Aug 24, 2025 |
| Pediatric Exclusivity(PED) | Feb 24, 2026 |
| Orphan Drug Exclusivity(ODE-405) | Aug 24, 2029 |
Drugs and Companies using IBRUTINIB ingredient
NCE-1 date: 24 February, 2025
Market Authorisation Date: 16 February, 2018
Dosage: TABLET; CAPSULE; SUSPENSION
How can I launch a generic of IMBRUVICA before it's drug patent expiration?
More Information on Dosage
IMBRUVICA family patents
7. Istodax patent expiration
Treatment: NA
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US4977138 | BRISTOL-MYERS | FR901228 substance and preparation thereof |
Aug, 2013
(12 years ago) | |
| US7611724 | BRISTOL-MYERS | Method of producing FR901228 |
Aug, 2021
(4 years ago) | |
| US7608280 | BRISTOL-MYERS | Method of producing FR901228 |
Aug, 2021
(4 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 05, 2014 |
| Orphan Drug Exclusivity(ODE) | Jun 16, 2018 |
| Orphan Drug Exclusivity(ODE-12) | Jun 16, 2018 |
Drugs and Companies using ROMIDEPSIN ingredient
NCE-1 date: 05 November, 2013
Market Authorisation Date: 05 November, 2009
Dosage: POWDER
How can I launch a generic of ISTODAX before it's drug patent expiration?
More Information on Dosage
ISTODAX family patents
8. Jaypirca patent expiration
Treatment: Adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (cll/sll) who have received at least two prior lines of thera...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US12220401 | LOXO ONCOL | Compounds useful as kinase inhibitors |
Dec, 2036
(10 years from now) | |
| US10695323 | LOXO ONCOL | Compounds useful as kinase inhibitors |
Dec, 2036
(10 years from now) | |
| US10342780 | LOXO ONCOL | Compounds useful as kinase inhibitors |
Dec, 2036
(10 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10464905 | LOXO ONCOL | Compounds useful as kinase inhibitors |
Dec, 2036
(10 years from now) | |
| US10918622 | LOXO ONCOL | Compounds useful as kinase inhibitors |
Dec, 2036
(10 years from now) | |
| US12109193 | LOXO ONCOL | Spray-dried dispersions, formulations, and polymorphs of (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1H-pyrazole-4-carboxamide |
Sep, 2041
(15 years from now) | |
| US12268666 | LOXO ONCOL | Spray-dried dispersions, formulations, and polymorphs of (S)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1H-pyrazole-4-carboxamide |
Jul, 2039
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 27, 2028 |
| Orphan Drug Exclusivity(ODE-424) | Jan 27, 2030 |
| Orphan Drug Exclusivity(ODE-451) | Dec 01, 2030 |
Drugs and Companies using PIRTOBRUTINIB ingredient
NCE-1 date: 27 January, 2027
Market Authorisation Date: 27 January, 2023
Dosage: TABLET
More Information on Dosage
JAYPIRCA family patents
9. Mozobil patent expiration
Treatment: Use in combination with granulocyte-colony stimulating factor (g-csf) to mobilize hematopoietic stem cells to peripheral blood for collection & subsequent autologous transplantation in patients with n...
MOZOBIL's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| USRE42152 | GENZYME | Aromatic-linked polyamine macrocyclic compounds with anti-HIV activity |
Dec, 2018
(7 years ago) | |
| US6987102 | GENZYME | Methods to mobilize progenitor/stem cells |
Jul, 2023
(2 years ago) | |
| US7897590 | GENZYME | Methods to mobilize progenitor/stem cells |
Jul, 2023
(2 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 15, 2013 |
| Orphan Drug Exclusivity(ODE) | Dec 15, 2015 |
Drugs and Companies using PLERIXAFOR ingredient
NCE-1 date: 15 December, 2012
Market Authorisation Date: 15 December, 2008
Dosage: SOLUTION
How can I launch a generic of MOZOBIL before it's drug patent expiration?
More Information on Dosage
MOZOBIL family patents
10. Revlimid patent expiration
Treatment: Use of revlimid (lenalidomide) while preventing the exposure of a fetus or other contraindicated individual to revlimid (lenalidomide); Use of revlimid (lenalidomide) for the treatment of mantle cell ...
REVLIMID's oppositions filed in EPO
REVLIMID IPR and PTAB Proceedings
Can you believe REVLIMID received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8288415 | BRISTOL MYERS SQUIBB | Pharmaceutical compositions of 3-(4-amino-1-oxoisoindolin-2yl)-piperidine-2,6-dione |
Jul, 2016
(9 years ago) | |
| US5635517 | BRISTOL MYERS SQUIBB | Method of reducing TNFα levels with amino substituted 2-(2,6-dioxopiperidin-3-yl)-1-oxo-and 1,3-dioxoisoindolines |
Oct, 2019
(6 years ago) | |
| US7855217 | BRISTOL MYERS SQUIBB | Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione |
Nov, 2024
(1 year, 1 month ago) | |
| US7465800 | BRISTOL MYERS SQUIBB | Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione |
Apr, 2027
(1 year, 3 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6561976 | BRISTOL MYERS SQUIBB | Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug |
Aug, 2018
(7 years ago) | |
| US7468363 | BRISTOL MYERS SQUIBB | Methods for treatment of cancers using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
Oct, 2023
(2 years ago) | |
| US9155730 | BRISTOL MYERS SQUIBB | Methods for treating non-hodgkin's lymphoma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione in combination with a second active agent |
May, 2023
(2 years ago) | |
| US8589188 | BRISTOL MYERS SQUIBB | Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug |
Aug, 2018
(7 years ago) | |
| US7119106 | BRISTOL MYERS SQUIBB | Pharmaceutical compositions of 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline |
Jul, 2016
(9 years ago) | |
| US8626531 | BRISTOL MYERS SQUIBB | Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated |
Oct, 2020
(5 years ago) | |
| US6755784 | BRISTOL MYERS SQUIBB | Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated |
Oct, 2020
(5 years ago) | |
| US6555554 | BRISTOL MYERS SQUIBB | Isoindolines, method of use, and pharmaceutical compositions |
Jul, 2016
(9 years ago) | |
| US6908432 | BRISTOL MYERS SQUIBB | Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug |
Aug, 2018
(7 years ago) | |
| US8648095 | BRISTOL MYERS SQUIBB | Methods for treating multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione in combination with proteasome inhibitor |
May, 2023
(2 years ago) | |
| US6281230 | BRISTOL MYERS SQUIBB | Isoindolines, method of use, and pharmaceutical compositions |
Jul, 2016
(9 years ago) | |
| US8315886 | BRISTOL MYERS SQUIBB | Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated |
Oct, 2020
(5 years ago) | |
| US8204763 | BRISTOL MYERS SQUIBB | Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug |
Aug, 2018
(7 years ago) | |
| US6045501 | BRISTOL MYERS SQUIBB | Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug |
Aug, 2018
(7 years ago) | |
| US6561977 | BRISTOL MYERS SQUIBB | Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated |
Oct, 2020
(5 years ago) | |
| US6315720 | BRISTOL MYERS SQUIBB | Methods for delivering a drug to a patient while avoiding the occurrence of an adverse side effect known or suspected of being caused by the drug |
Oct, 2020
(5 years ago) | |
| US8288415 | BRISTOL MYERS SQUIBB | Pharmaceutical compositions of 3-(4-amino-1-oxoisoindolin-2yl)-piperidine-2,6-dione |
Jul, 2016
(9 years ago) | |
| US9393238 | BRISTOL MYERS SQUIBB | Methods for treating non-hodgkin's lymphoma with 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione in combination with a second active agent |
May, 2023
(2 years ago) | |
| US7189740 | BRISTOL MYERS SQUIBB | Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes |
Apr, 2023
(2 years ago) | |
| US7968569 | BRISTOL MYERS SQUIBB | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
Oct, 2023
(2 years ago) | |
| US8530498 | BRISTOL MYERS SQUIBB | Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)piperidine-2,6-dione |
May, 2023
(2 years ago) | |
| US8492406 | BRISTOL MYERS SQUIBB | Methods for treatment of follicular lymphoma using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione |
Oct, 2023
(2 years ago) | |
| US9056120 | BRISTOL MYERS SQUIBB | Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine |
Apr, 2023
(2 years ago) | |
| US9101621 | BRISTOL MYERS SQUIBB | Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation |
May, 2023
(2 years ago) | |
| US5635517 | BRISTOL MYERS SQUIBB | Method of reducing TNFα levels with amino substituted 2-(2,6-dioxopiperidin-3-yl)-1-oxo-and 1,3-dioxoisoindolines |
Oct, 2019
(6 years ago) | |
| US8404717 | BRISTOL MYERS SQUIBB | Methods of treating myelodysplastic syndromes using lenalidomide |
Apr, 2023
(2 years ago) | |
| US9101622 | BRISTOL MYERS SQUIBB | Methods for treating newly diagnosed multiple myeloma 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione in combination with dexamethasone |
May, 2023
(2 years ago) | |
| US8741929 | BRISTOL MYERS SQUIBB | Methods using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of mantle cell lymphomas |
Mar, 2028
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE) | Jun 05, 2020 |
| New Indication(I-672) | Jun 05, 2016 |
| New Strength(NS) | Jun 05, 2016 |
| New Indication(I-706) | Feb 17, 2018 |
| Orphan Drug Exclusivity(ODE-49) | Jun 05, 2020 |
| Orphan Drug Exclusivity(ODE-88) | Feb 17, 2022 |
| New Indication(I-796) | May 28, 2022 |
| New Indication(I-797) | May 28, 2022 |
| Orphan Drug Exclusivity(ODE-131) | Feb 22, 2024 |
| Orphan Drug Exclusivity(ODE-241) | May 28, 2026 |
| Orphan Drug Exclusivity(ODE-245) | May 28, 2026 |
Drugs and Companies using LENALIDOMIDE ingredient
Market Authorisation Date: 21 December, 2011
Dosage: CAPSULE
How can I launch a generic of REVLIMID before it's drug patent expiration?
More Information on Dosage
REVLIMID family patents
11. Targretin patent expiration
Treatment: Topical treatment of cutaneous lesions in patients with cutaneous t-cell lymphoma (stage ia and ib) who have refractory or persistent diseas...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5780676 | BAUSCH | Compounds having selective activity for Retinoid X Receptors, and means for modulation of processes mediated by Retinoid X Receptors |
Jul, 2015
(10 years ago) | |
| US5962731 | BAUSCH | Compounds having selective activity for retinoid X receptors, and means for modulation of processes mediated by retinoid X receptors |
Oct, 2016
(9 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-164) | Jul 29, 2018 |
Drugs and Companies using BEXAROTENE ingredient
Market Authorisation Date: 29 December, 1999
Dosage: CAPSULE; GEL
More Information on Dosage
TARGRETIN family patents
12. Tazverik patent expiration
Treatment: Method of treating a lung metastasis of epithelioid sarcoma; Method of treating relapsed or refractory follicular lymphoma; Method of treati...
TAZVERIK's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9394283 | EPIZYME INC | Salt form of a human histone methyltransferase EZH2 inhibitor |
Apr, 2033
(7 years from now) | |
| US11052093 | EPIZYME INC | Aryl-or heteroaryl-substituted benzene compounds |
Sep, 2031
(5 years from now) | |
| US9090562 | EPIZYME INC | Aryl- or heteroaryl-substituted benzene compounds |
Sep, 2031
(5 years from now) | |
| US12168015 | EPIZYME INC | Aryl-or heteroaryl-substituted benzene compounds |
Sep, 2031
(5 years from now) | |
| US8410088 | EPIZYME INC | Aryl- or heteroaryl-substituted benzene compounds |
Jan, 2034
(8 years from now) | |
| US10821113 | EPIZYME INC | Salt form of a human histone methyltransferase EZH2 inhibitor |
Apr, 2033
(7 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9872862 | EPIZYME INC | Salt form of a human histone methyltransferase EZH2 inhibitor |
Apr, 2033
(7 years from now) | |
| US9522152 | EPIZYME INC | Aryl- or heteroaryl-substituted benzene compounds |
Apr, 2032
(6 years from now) | |
| US9889138 | EPIZYME INC | Method for treating cancer |
Oct, 2035
(9 years from now) | |
| US8765732 | EPIZYME INC | Aryl- or heteroaryl-substituted benzene compounds |
Sep, 2031
(5 years from now) | |
| US9549931 | EPIZYME INC | Aryl- or heteroaryl-substituted benzene compounds |
Sep, 2031
(5 years from now) | |
| US9334527 | EPIZYME INC | Inhibitors of human EZH2, and methods of use thereof |
Sep, 2031
(5 years from now) | |
| US9333217 | EPIZYME INC | Inhibitors of human EZH2, and methods of use thereof |
Sep, 2031
(5 years from now) | |
| US8691507 | EPIZYME INC | Inhibitors of human EZH2 and methods of use thereof |
Sep, 2031
(5 years from now) | |
| US9175331 | EPIZYME INC | Inhibitors of human EZH2, and methods of use thereof |
Sep, 2031
(5 years from now) | |
| US8895245 | EPIZYME INC | Inhibitors of human EZH2 and methods of use thereof |
Sep, 2031
(5 years from now) | |
| US9949999 | EPIZYME INC | Inhibitors of human EZH2, and methods of use thereof |
Sep, 2031
(5 years from now) | |
| US10369155 | EPIZYME INC | Method for treating cancer |
Oct, 2035
(9 years from now) | |
| US10420775 | EPIZYME INC | Aryl-or heteroaryl-substituted benzene compounds |
Sep, 2031
(5 years from now) | |
| US12168014 | EPIZYME INC | Method for treating cancer |
May, 2038
(12 years from now) | |
| US12162865 | EPIZYME INC | Methods of treating cancer |
Jun, 2034
(8 years from now) | |
| US12168016 | EPIZYME INC | Aryl-OR heteroaryl-substituted benzene compounds |
Sep, 2031
(5 years from now) | |
| US10155002 | EPIZYME INC | Aryl- or heteroaryl-substituted benzene compounds |
Sep, 2031
(5 years from now) | |
| US9688665 | EPIZYME INC | Methods of treating cancer |
Aug, 2034
(8 years from now) | |
| US9855275 | EPIZYME INC | Aryl-or heteroaryl-substituted benzene compounds |
Sep, 2031
(5 years from now) | |
| US10245269 | EPIZYME INC | Salt form of a human histone methyltransferase EZH2 inhibitor |
Apr, 2033
(7 years from now) | |
| US12161645 | EPIZYME INC | Aryl-or heteroaryl-substituted benzene compounds |
Sep, 2031
(5 years from now) | |
| US11491163 | EPIZYME INC | Salt form of a human histone methyltransferase EZH2 inhibitor |
Apr, 2033
(7 years from now) | |
| US10786511 | EPIZYME INC | Method for treating cancer |
Dec, 2035
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-835) | Jun 18, 2023 |
| New Indication(I-836) | Jun 18, 2023 |
| New Chemical Entity Exclusivity(NCE) | Jan 23, 2025 |
| Orphan Drug Exclusivity(ODE-299) | Jan 23, 2027 |
| Orphan Drug Exclusivity(ODE-314) | Jun 18, 2027 |
Drugs and Companies using TAZEMETOSTAT HYDROBROMIDE ingredient
NCE-1 date: 24 January, 2024
Market Authorisation Date: 23 January, 2020
Dosage: TABLET
More Information on Dosage
TAZVERIK family patents
13. Treanda patent expiration
Treatment: For use in the treatment of patients with chronic lymphocytic leukemia and/or non-hodgkins lymphoma; For use in the treatment of patients wi...
TREANDA's oppositions filed in EPO
TREANDA IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8445524 | CEPHALON | Solid forms of bendamustine hydrochloride |
Mar, 2029
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8791270 | CEPHALON | Bendamustine pharmaceutical compositions |
Jan, 2026
(2 days from now) | |
| US8883836 | CEPHALON | Solid forms of bendamustine hydrochloride |
Mar, 2029
(3 years from now) | |
| US9533955 | CEPHALON | Solid forms of bendamustine hydrochloride |
Mar, 2029
(3 years from now) | |
| US8344006 | CEPHALON | Liquid formulations of bendamustine |
Sep, 2029
(3 years from now) | |
| US8669279 | CEPHALON | Solid forms of bendamustine hydrochloride |
Mar, 2029
(3 years from now) | |
| US8609863 | CEPHALON | Bendamustine pharmaceutical compositions |
Jan, 2026
(2 days from now) | |
| US8895756 | CEPHALON | Bendamustine pharmaceutical compositions |
Jan, 2026
(2 days from now) | |
| US8436190 | CEPHALON | Bendamustine pharmaceutical compositions |
Oct, 2030
(4 years from now) | |
|
US8436190 (Pediatric) | CEPHALON | Bendamustine pharmaceutical compositions |
Apr, 2031
(5 years from now) | |
|
US8445524 (Pediatric) | CEPHALON | Solid forms of bendamustine hydrochloride |
Sep, 2029
(3 years from now) | |
|
US8883836 (Pediatric) | CEPHALON | Solid forms of bendamustine hydrochloride |
Sep, 2029
(3 years from now) | |
|
US8669279 (Pediatric) | CEPHALON | Solid forms of bendamustine hydrochloride |
Sep, 2029
(3 years from now) | |
|
US8791270 (Pediatric) | CEPHALON | Bendamustine pharmaceutical compositions |
Jul, 2026
(6 months from now) | |
|
US8344006 (Pediatric) | CEPHALON | Liquid formulations of bendamustine |
Mar, 2030
(4 years from now) | |
|
US8609863 (Pediatric) | CEPHALON | Bendamustine pharmaceutical compositions |
Jul, 2026
(6 months from now) | |
|
US8895756 (Pediatric) | CEPHALON | Bendamustine pharmaceutical compositions |
Jul, 2026
(6 months from now) | |
|
US9533955 (Pediatric) | CEPHALON | Solid forms of bendamustine hydrochloride |
Sep, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-580) | Oct 31, 2011 |
| New Chemical Entity Exclusivity(NCE) | Mar 20, 2013 |
| Pediatric Exclusivity(PED) | May 01, 2016 |
| Orphan Drug Exclusivity(ODE) | Oct 31, 2015 |
| ODE*(ODE*) | Dec 07, 2022 |
Drugs and Companies using BENDAMUSTINE HYDROCHLORIDE ingredient
NCE-1 date: 02 May, 2015
Market Authorisation Date: 01 May, 2009
Dosage: POWDER; SOLUTION
How can I launch a generic of TREANDA before it's drug patent expiration?
More Information on Dosage
TREANDA family patents
14. Ukoniq patent expiration
Treatment: Relapsed or refractory follicular lymphoma (fl) who have received at least three prior lines of systemic therapy; Relapsed or refractory mar...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9969740 | TG THERAPS | Forms of a PI3K delta selective inhibitor for use in pharmaceutical formulations |
May, 2035
(9 years from now) | |
| US10570142 | TG THERAPS | Selective PI3K delta inhibitors |
Jul, 2033
(7 years from now) | |
| US10414773 | TG THERAPS | Forms of a PI3K delta selective inhibitor for use in pharmaceutical formulations |
May, 2035
(9 years from now) | |
| US9150579 | TG THERAPS | Selective PI3K delta inhibitors |
Jul, 2033
(7 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10072013 | TG THERAPS | Selective PI3K delta inhibitors |
Jul, 2033
(7 years from now) | |
| US10947244 | TG THERAPS | Forms of a PI3K delta selective inhibitor for use in pharmaceutical formulations |
May, 2035
(9 years from now) | |
| US9669033 | TG THERAPS | Selective PI3K delta inhibitors |
Jul, 2033
(7 years from now) | |
| US10981919 | TG THERAPS | Selective PI3K delta inhibitors |
Jul, 2033
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Feb 05, 2026 |
| Orphan Drug Exclusivity(ODE-343) | Feb 05, 2028 |
| Orphan Drug Exclusivity(ODE-344) | Feb 05, 2028 |
Drugs and Companies using UMBRALISIB TOSYLATE ingredient
NCE-1 date: 05 February, 2025
Market Authorisation Date: 05 February, 2021
Dosage: TABLET
More Information on Dosage
UKONIQ family patents
15. Zolinza patent expiration
Treatment: Treatment of cutaneous manifestations in patients with cutaneous t-cell lymphoma (ctcl)
ZOLINZA's oppositions filed in EPO
Can you believe ZOLINZA received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7456219 | MSD SUB MERCK | Polymorphs of suberoylanilide hydroxamic acid |
Mar, 2027
(1 year, 1 month from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| USRE38506 | MSD SUB MERCK | Potent inducers of terminal differentiation and methods of use thereof |
Nov, 2013
(12 years ago) | |
| US8101663 | MSD SUB MERCK | Polymorphs of suberoylanilide hydroxamic acid |
Mar, 2023
(2 years ago) | |
| US7652069 | MSD SUB MERCK | Polymorphs of suberoylanilide hydroxamic acid |
Mar, 2023
(2 years ago) | |
| US7732490 | MSD SUB MERCK | Methods of treating cancer |
Mar, 2023
(2 years ago) | |
| US7399787 | MSD SUB MERCK | Methods of treating cancer with HDAC inhibitors |
Feb, 2025
(10 months ago) | |
| US8067472 | MSD SUB MERCK | Methods of treating Hodgkin's and non-Hodgkin's lymphoma |
Mar, 2023
(2 years ago) | |
| US7851509 | MSD SUB MERCK | Polymorphs of suberoylanilide hydroxamic acid |
Feb, 2024
(1 year, 10 months ago) | |
| US8450372 | MSD SUB MERCK | Formulations of suberoylanilide hydroxamic acid and methods for producing same |
Mar, 2028
(2 years from now) | |
| US8093295 | MSD SUB MERCK | Formulations of suberoylanilide hydroxamic acid and methods for producing the same |
May, 2026
(4 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 06, 2011 |
| Orphan Drug Exclusivity(ODE) | Oct 06, 2013 |
Drugs and Companies using VORINOSTAT ingredient
NCE-1 date: 06 October, 2010
Market Authorisation Date: 06 October, 2006
Dosage: CAPSULE
More Information on Dosage
ZOLINZA family patents
16. Zydelig patent expiration
Treatment: For the treatment of patients with cll, fl, or sll; In combination with rituximab, for the treatment of patients with relapsed chronic lymphocytic leukemia (cll); Inhibition on pi3k kinase; For the tr...
ZYDELIG's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6800620 | GILEAD SCIENCES INC | Inhibitors of human phosphatidylinositol 3-kinase delta |
Apr, 2021
(4 years ago) | |
| US8637533 | GILEAD SCIENCES INC | Inhibitors of human phosphatidylinositol 3-kinase delta |
Apr, 2021
(4 years ago) | |
| US8492389 | GILEAD SCIENCES INC | Inhibitors of human phosphatidylinositol 3-kinase delta |
Apr, 2021
(4 years ago) | |
| US8138195 | GILEAD SCIENCES INC | Inhibitors of human phosphatidylinositol 3-kinase delta |
Apr, 2021
(4 years ago) | |
| US6949535 | GILEAD SCIENCES INC | Inhibitors of human phosphatidyl-inositol 3-kinase delta |
Apr, 2021
(4 years ago) | |
| US8865730 | GILEAD SCIENCES INC | Polymorphic forms of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one |
Mar, 2033
(7 years from now) | |
| USRE44638 | GILEAD SCIENCES INC | Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta |
Aug, 2025
(5 months ago) | |
| US10730879 | GILEAD SCIENCES INC | Polymorphic forms of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one |
Mar, 2033
(7 years from now) | |
| US9469643 | GILEAD SCIENCES INC | Polymorphic forms of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one |
Sep, 2033
(7 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8980901 | GILEAD SCIENCES INC | 5-fluoro-3-phenyl-2[1-(9H-purin-6-ylamino)propyl]-3H-quinazolin-4-one and 6-fluoro-3-phenyl-2-[1-(9H-purin-6-ylamino)ethyl]-3H-quinazolin-4-one as inhibitors of human phosphatidylinositol 3-kinase delta |
May, 2025
(7 months ago) | |
| US9492449 | GILEAD SCIENCES INC | Therapies for hematologic malignancies |
Mar, 2030
(4 years from now) | |
| US9149477 | GILEAD SCIENCES INC | 5-fluoro-3-phenyl-2-[1-(9h-purin-6-ylamino)propyl]-3h-quinazolin-4-one as an inhibitor of human phosphatidylinositol 3-kinase delta |
May, 2025
(7 months ago) | |
| USRE44599 | GILEAD SCIENCES INC | Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta |
Jul, 2025
(5 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 23, 2019 |
| Orphan Drug Exclusivity(ODE) | Jul 23, 2021 |
| Orphan Drug Exclusivity(ODE-70) | Jul 23, 2021 |
| Orphan Drug Exclusivity(ODE-71) | Jul 23, 2021 |
Drugs and Companies using IDELALISIB ingredient
NCE-1 date: 23 July, 2018
Market Authorisation Date: 23 July, 2014
Dosage: TABLET
How can I launch a generic of ZYDELIG before it's drug patent expiration?
More Information on Dosage
ZYDELIG family patents